CORRECTION: Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call

Rhea-AI Summary

Spectral AI (NASDAQ: MDAI) has issued a correction to its earlier announcement regarding the scheduling of its 2024 fourth quarter and full year financial results. The company will now release its financial results on Thursday, March 27, 2025, after market close, followed by a conference call at 5:00 pm Eastern Time.

Spectral AI, known for its DeepView® System which received FDA Breakthrough Device Designation in 2018, specializes in using multi-spectral imaging and AI algorithms to predict burn healing potential. Investors can participate in the conference call by dialing 844-481-3008 (U.S.) or 412-317-1892 (International). A simultaneous webcast will be available through the Events & Presentations section of the company's Investor Relations webpage.

DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Spectral AI, Inc. (NASDAQ: MDAI), the reporting date of the financial results for the fourth quarter was incorrectly stated, and has been amended. The corrected release follows:

Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, March 27, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results.

Investors interested in participating in the live call can dial:

• 844-481-3008 - U.S.
• 412-317-1892 - International

A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at https://investors.spectral-ai.com/news-events/events.

About Spectral AI

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown^®” with its DeepView^® System. DeepView^® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView^® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView^®, visit www.spectral-ai.com.

Forward Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,”
“may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward- looking statements.

Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward- looking statements.

For Media and Investor Relations, please contact:

David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free – U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com

FAQ

When will Spectral AI (MDAI) release its Q4 2024 financial results?

Spectral AI will release its Q4 and full year 2024 financial results on Thursday, March 27, 2025, after the stock market closes.

How can investors join Spectral AI's (MDAI) Q4 2024 earnings call?

Investors can join by dialing 844-481-3008 (U.S.) or 412-317-1892 (International) at 5:00 pm Eastern Time on March 27, 2025.

What is Spectral AI's (MDAI) DeepView® System breakthrough designation status?

The DeepView® System received Breakthrough Device Designation from the FDA in 2018.

Where can investors access the webcast of MDAI's Q4 2024 earnings call?

The webcast can be accessed through the Events & Presentations section at https://investors.spectral-ai.com/news-events/events

What technology does Spectral AI's (MDAI) DeepView® System use?

The DeepView® System uses multi-spectral imaging and AI algorithms to predict burn healing potential.